フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
GSK PLC 23 December 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a...
GSK PLC 20 December 2024 GSK plc Block listing Application Application has been made to the Financial Conduct Authority and the London...
GSK PLC on Friday said a trial of two ovarian cancer treatments met its primary endpoint but did not meet a key secon ...
GSK PLC 20 December 2024 Issued: 20 December 2024, London UK GSK announces FIRST trial met its primary endpoint of progression free survival...
GSK PLC on Monday reported a triple dose of good news with positive regulatory updates on two leading cancer drugs. ...
GSK PLC 16 December 2024 Issued: 16 December 2024, London UK Jemperli (dostarlimab) receives US FDA Breakthrough Therapy Designation for...
GSK PLC 16 December 2024 Issued: 16 December 2024, London UK GSK's B7-H3-targeted antibody-drug conjugate, GSK'227, receives EMA Priority...
GSK PLC 16 December 2024 Issued: 16 December 2024, London UK Jemperli (dostarlimab) plus chemotherapy receives positive CHMP opinion to...
GSK PLC 12 December 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA...
based pharmaceuticals firm - Says Dreamm-7 trial shows sustained overall survival benefit for Blenrep, the brand name ...
GSK PLC 09 December 2024 Issued: 9 December 2024, London UK Blenrep shows significant overall survival benefit, reducing the risk of death...
GSK PLC on Monday received a double-dose of good news with its Nucala and Blenrep products receiving positive indicat ...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約